Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0789
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2614
    -0.0008 (-0.06%)
     
  • USD/JPY

    151.3040
    -0.0680 (-0.04%)
     
  • Bitcoin USD

    70,102.05
    -661.89 (-0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling

rheumatoid arthritis
rheumatoid arthritis

(A hand of someone who has rheumatoid arthritis.david__jones/Flickr Creative Commons)

The FDA just rejected a new daily pill to treat rheumatoid arthritis.

Pharmaceutical companies Lilly and Incyte said on Friday that their drug, baricitinib, had been issued a complete response letter, which explains why the drug didn't get approval.

In its letter, the FDA told Lilly and Incyte that it wanted more data on what the right dose for the drug is. The FDA also wants more data about potential safety issues.

Incyte was down 10% in pre-market trading on Monday after the holiday while Lilly was down as much as 6%.

The FDA had previously pushed back its review date of baricitinib by three months. Even so, analysts largely expected the FDA to approve baricitinib, especially after the European Commission approved the drug in February. If approved would have been a competitor to Pfizer's Xeljanz.

"We are disappointed with this action. We remain confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate-to-severe RA," Christi Shaw, Lilly Bio-Medicines president said in a news release. The companies plan to resubmit the drug to the FDA.

Rheumatoid arthritis is a common, chronic inflammatory condition that affects the joints. There are a number of ways to treat the disease, such as the chemotherapy drug methotrexate.

Screen Shot 2017 04 17 at 8.45.12 AM
Screen Shot 2017 04 17 at 8.45.12 AM

(Markets Insider)

NOW WATCH: Amateur astronomers just found objects in space that could lead to the biggest discovery of our Solar System in over 150 years



More From Business Insider

Advertisement